ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc., an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on March 25, 2021. The filing serves to announce the company's financial results for the quarter and full year ended December 31, 2020, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) but are not detailed in the body of this Form 8-K.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed in the text of this filing. The document solely references the issuance of the press release containing the results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of that section nor incorporated by reference in other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in this document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 25, 2021) for actual financial figures.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbols (NDRA for Common Stock, NDRAW for Warrants) on The Nasdaq Stock Market LLC.
- Check subsequent filings for the full financial statements referenced in the press release.